Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
67%(2 trials)

Phase Distribution

Ph phase_4
2
40%
Ph not_applicable
1
20%
Ph phase_2
1
20%
Ph phase_3
1
20%

Phase Distribution

0

Early Stage

1

Mid Stage

3

Late Stage

Phase Distribution5 total trials
Phase 2Efficacy & side effects
1(20.0%)
Phase 3Large-scale testing
1(20.0%)
Phase 4Post-market surveillance
2(40.0%)
N/ANon-phased studies
1(20.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(3)
Terminated(1)
Other(1)

Detailed Status

Completed3
Withdrawn1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (20.0%)
Phase 31 (20.0%)
Phase 42 (40.0%)
N/A1 (20.0%)

Trials by Status

withdrawn120%
completed360%
unknown120%

Recent Activity

0 active trials
Showing 5 of 5
completedphase_4

Effect of Tenofovir on Genital Herpes Simplex Virus (HSV) Shedding

NCT01448616
completedphase_4

Sexual Absorption of Vaginal Progesterone

NCT01959464
unknownphase_2

Saginil in vs. Placebo for Gynecologic Oncology Patients Affected by Vaginitis

NCT01420510
withdrawnnot_applicable

Vaginal Progesterone as a Treatment for Women Active Preterm Labor

NCT01206998
completedphase_3

Vaginal Progesterone to Reduce the Risk of Another Preterm Birth

NCT00086177

Clinical Trials (5)

Showing 5 of 5 trials
NCT01448616Phase 4

Effect of Tenofovir on Genital Herpes Simplex Virus (HSV) Shedding

Completed
NCT01959464Phase 4

Sexual Absorption of Vaginal Progesterone

Completed
NCT01420510Phase 2

Saginil in vs. Placebo for Gynecologic Oncology Patients Affected by Vaginitis

Unknown
NCT01206998Not Applicable

Vaginal Progesterone as a Treatment for Women Active Preterm Labor

Withdrawn
NCT00086177Phase 3

Vaginal Progesterone to Reduce the Risk of Another Preterm Birth

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5